- Report
- March 2025
- 185 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- October 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- May 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 186 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- July 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 282 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 188 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 194 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 132 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 196 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- October 2025
- 137 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- July 2025
- 350 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- January 2026
- 149 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- July 2025
- 275 Pages
Global
From €4375EUR$4,995USD£3,797GBP
- Report
- June 2025
- 275 Pages
Global
From €4375EUR$4,995USD£3,797GBP

Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing.
The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place.
Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more